Sponsors (62)
The bill channels new federal funding and reporting to accelerate brain tumor research, expand trial access, and improve survivorship care—benefiting patients and researchers—but it increases taxpayer cost, shifts resources toward prioritized research areas, and creates administrative, safety, privacy, and equity risks that will need mitigation.
Patients with brain tumors (adult and pediatric) gain expanded, targeted federal research funding and multi‑institutional programs that increase the pace of clinical trials and the chance of new therapies (including cellular immunotherapies like CAR‑T).
Scientists, researchers, medical centers, and academic institutions get more stable funding, improved access to shared biospecimens, and support for preclinical/early‑phase trials, accelerating translation of discoveries into treatments.
Patients (including rural and racial/ethnic minority communities) receive expanded outreach, information on biomarker testing and trial options, and clearer eligibility guidance that can increase awareness and access to appropriate clinical trials.
Taxpayers face increased federal spending from multiple new authorizations (including multi‑million dollar annual program funding and administrative costs).
Patients who enroll in novel cellular therapy trials (e.g., CAR‑T) face real risks of serious adverse effects from early‑phase experimental treatments.
Concentrating funds and investigator attention on glioblastoma and cellular immunotherapies may divert research resources and clinical focus away from other cancers, broader oncology needs, or primary care services.
Based on analysis of 12 sections of legislative text.
Authorizes NIH/HHS programs, public biospecimen reporting, outreach, survivorship pilot grants, and FDA guidance to expand brain tumor research, care, and clinical trial access.
Introduced April 9, 2025 by Brian K. Fitzpatrick · Last progress April 9, 2025
Directs federal health agencies to boost research, clinical trials access, and care for people with brain tumors. It requires NIH to publish and maintain a public, searchable listing of NIH-funded brain tumor biospecimen collections, creates new NCI programs to advance glioblastoma therapeutics and cellular immunotherapies, funds outreach to increase awareness of cancer clinical trials and biomarker testing, supports pilot grants for survivorship care models, and orders FDA guidance to reduce routine exclusion of brain tumor patients from clinical trials. Sets deadlines and reporting rules for biospecimen collections, authorizes multi-year funding for the new research programs, and includes enforcement authority for repeated reporting violations; several programs are aimed at pediatric and adult brain tumor patients, clinicians, and researchers and emphasize multi-institution collaboration and equitable outreach.